Table 2 Summary of included studies (n = 41)
Author (date) | Country | Study design | gMG data type (n/N) | gMG classification tool | PROMs |
|---|---|---|---|---|---|
Akkan Suzan 2022 [1] | Turkey | Case–control | gMG subgroup data (30/53) | MGFA IIA | Symptom-specific (FAS, FIS, BDI, ESS) |
Alanazy 2019 [3] | Saudi Arabia | Cross-sectional | gMG subgroup data (82/104) | Author reported | Symptom-specific (PHQ-9) |
Ambrogi 2012 [4] | Italy | Retrospective cohort | All gMG (59/59) | MGFA III | Generic (SF-36) |
Andersen 2021 [5] | Denmark | Cross-sectional | All gMG (100/100) | Author reported | Generic (EQ-5D-3L, EQ-5D-VAS, PASS) Symptom-specific (MFI-20, MDI) Disease-specific (MG-ADL, MG-QoL 15) |
Aysal 2013 [6] | Turkey | Cross-sectional | gMG subgroup data (QoL by MG stage) and > 80% gMG (QoL by treatment) (36/42) | Osserman IIA-IIB | Symptom-specific (BDI, BAI, HAM-D, HAM-A) |
Bachmann 2008 [7] | Germany | Prospective cohort | All gMG (106/106) | Osserman II-IV | Generic (EORTC QLQ) |
Baram 2021 [8] | Iraq | Retrospective cohort |  > 80% gMG with no subgroup data (44/48) | MGFA IIA-IVB | Disease-specific (MG-ADL) |
Bartel 1995 [9] | South Africa | Case–control |  > 80% gMG with no subgroup data (15/16) | Author reported | Generic (POMS) Symptom-specific (IPAT anxiety scale) |
Basta 2012 [10] | Serbia | Cross-sectional | gMG subgroup data (120/230) | MGFA IIA-IIIB | Generic (SF-36) |
Birnbaum 2021 [11] | France | Case–control | All gMG (33/33) | MGFA II-III | Disease-specific (MG-ADL, MG-QoL 15) |
Busch 1996 [13] | Germany | Retrospective cohort |  > 80% gMG with no subgroup data (61/65) | Modified Osserman II-IV | Generic (EORTC) |
Cioncoloni 2016 [15] | Italy | Cross-sectional | gMG subgroup data (29/41) | MGFA IIA-IVB | Disease-specific (subjective patient evaluation [first item of the IMGQ]) |
De Freitas Fregonezi 2006 [16] | Spain | Prospective cohort | All gMG (20/20) | Osserman IIA-IIB | Generic (SF-36) |
De Lapiscina 2012 [17] | Spain | Cross-sectional | gMG subgroup data (23/54) | Author reported | Symptom-specific (ESS, PSQI) Disease-specific (MG-QoL 15) |
Dewilde 2022 [18] | Belgium, Canada, Germany, Italy, Japan, Spain, UK, USA | Prospective cohort | gMG subgroup data (NR/617) | MGFA II-IV | Generic (EQ-5D-5L) |
Happe 2004 [23] | Austria | Case–control |  > 80% gMG with no subgroup data (16/17) | Osserman II | Generic (QLI) Symptom-specific (ESS, SDS, SAS, PSQI, SSA) |
Hoffmann 2016 [24] | Germany | Cross-sectional | gMG subgroup data (116/200) | MGFA II-IV | Symptom-specific (CFQ, HADS-D, HADS-A, ISI) |
Jastrzebska 2019 [26] | Poland | Cross-sectional |  > 80% gMG with no subgroup data (87/101) | MGFA | Disease-specific (MG-ADL) |
Jordan 2017 [29] | Germany | Case–control | All gMG (33/33) | MGFA | Generic (10-point VAS) Symptom-specific (CES-D, PSQI, FSMC) Disease-specific (MGFS, MG-ADL, MG-QoL 15) |
Jordan 2017 [28] | |||||
Kaukiainen 1977 [30] | Finland | Cross-sectional | gMG subgroup data (169/181) | Oosterhuis | None (economic only) |
Kotan 2016 [31] | Turkey | Cross-sectional |  > 80% gMG with no subgroup data (43/52) | Author reported | Generic (PAIS-SR, MSPSS, PTGI, SF-36) Symptom-specific (HADS-D, HADS-A) |
Law 2021 [32] | France, UK, USA | Retrospective cohort | All gMG (NR) | Author reported | Patient lived experience |
Lehnerer 2021 [33] | Germany | Cross-sectional | gMG subgroup data (1,127/1,660) | Author reported | Generic (ESSI) Symptom-specific (HADS-D, HADS-A, CFQ) Disease-specific (MG-ADL, MG-QoL 15) |
Ohlraun 2015 [36] | Germany | Cross-sectional |  > 80% gMG with no subgroup data (642/791) | MGFA II-V | Family planning |
Onyekwulu 2010 [37] | Nigeria | Retrospective cohort | All gMG (11/11) | Osserman IV | None (economic only) |
Padua 2001 [38] | Italy | Prospective cohort |  > 80% gMG with no subgroup data (44/46) | Osserman II-IV | Generic (SF-36) |
Peres 2017 [40] | Portugal | Retrospective cohort | All gMG (6/6) | Author reported | Generic (EQ-5D) Disease-specific (MG-QoL 15) |
Raggi 2010 [41] | Italy | Prospective cohort | gMG subgroup data (48/102) | MGFA II-IV | Generic (SF-36) |
Rodolico 2021 [43] | Italy | Retrospective cohort | All gMG (15/15) | MGFA II-III | Disease-specific (MG-ADL) |
Roth 2002 [44] | Switzerland | Retrospective cohort | All gMG (23/23) | Osserman II-IV, Oosterhuis | Generic (subjective patient evaluation) |
Ruckert 2003 [45] | Germany | Retrospective cohort | All gMG (182/182) | Osserman II-III | Disease-specific (MG-ADL) |
Ruiter 2021 [46] | Belgium | Cross-sectional | gMG subgroup data (NR/NR) | Positive scores on MG-ADL item(s) 5 and/or 6 | Symptom-specific (CIS-f) |
Sabre 2017 [47] | Estonia | Cross-sectional |  > 80% gMG with no subgroup data (29/36) | Author reported | Symptom-specific (FSS) |
Sitek 2009 [48] | Poland | Case–control |  > 80% gMG with no subgroup data (29/33) | MGFA II-IV | Symptom-specific (BDI) |
Stankovic 2018 [49] | Serbia | Prospective cohort |  > 80% gMG with no subgroup data (70/73) | MGFA IIA-IV | Generic (MSPSS, AIS, SF-36) Symptom-specific (HAM-A, HAM-D) |
Stojanov 2019 [50] | Serbia | Prospective cohort | gMG subgroup data (NR/70) | MGFA II-IV | Generic (SF-36) Symptom-specific (HAM-A, HAM-D) Disease-specific (MG-QoL 15r) |
Szczudlik 2020 [51] | Poland | Cross-sectional | gMG subgroup data (228/339) | MGFA IIA-IVB | Generic (SF-36) |
Tascilar 2018 [52] | Turkey | Case–control | All gMG (19/19) | MGFA II-III | Symptom-specific (ESS, PSQI, FSS, HAM-A, HAM-D) Disease-specific (MG-QoL 15) |
Thomsen 2021 [54] | Denmark | Prospective cohort |  > 80% gMG with no subgroup data (95/107) | MGFA II-IV | Disease-specific (MG-ADL, MG-QoL 15) |
Westerberg 2018 [55] | Sweden | Cross-sectional | gMG subgroup data (31/40) | Author reported | Disease-specific (MG-QoL 15) |